Using Pharmacy Signals To Spot Antimicrobial Resistance Earlier

Antimicrobial resistance rarely appears as a single dramatic event. It often develops through small changes in prescribing, treatment failure, medicine demand, and local transmission. Pharmacy sales can reveal some of these changes before laboratory reports are complete, especially when clinicians begin using broader-spectrum or second-line antibiotics more frequently.

For public-health teams, the value lies in combining pharmacy information with other syndromic surveillance channels. A rise in dispensing may reflect a genuine increase in resistant infections, but it may also result from seasonal illness, a prescribing campaign, a medicine shortage, or changes in access to general practitioners. The signal becomes more useful when it is compared with consultations, hospital presentations, school absenteeism, ambulance activity, and microbiology results.

Australia offers a practical setting for this approach. Large metropolitan areas such as Sydney, Melbourne, Brisbane, Perth, and Adelaide have extensive community pharmacy networks, while rural and remote communities may have fewer dispensing points and longer travel distances for care. A surveillance method must account for these differences rather than treating every sales increase as epidemiologically equivalent.

The aim is early warning, not an automatic diagnosis of resistance. Pharmacy data can help identify where further investigation is needed, allowing public-health authorities and antimicrobial stewardship teams to examine prescribing patterns, culture results, medicine availability, and patient outcomes before a resistant strain becomes widespread.

Why Second-Line Antibiotics Can Act As A Warning Signal

First-line antibiotics are generally preferred because they are effective for common infections, have an established safety profile, and create less selective pressure than many broader-spectrum alternatives. Second-line medicines may be used when a patient has an allergy, has not responded to initial treatment, has a complicated infection, or is thought to carry a resistant organism. A sustained increase in their use can therefore indicate a change in clinical circumstances.

Pharmacy surveillance focuses on dispensing events, product type, quantity, location, and timing. Depending on the available dataset, it may also include age group, prescriber specialty, repeat dispensing, or whether the medicine was supplied under the Pharmaceutical Benefits Scheme. In Australia, PBS data can support population-level analysis, while private prescriptions and hospital-only supply may require separate sources.

The most informative measure is usually a rate or proportion rather than a raw count. Analysts might compare second-line antibiotic dispensing with total antibiotic dispensing, adjust for population size, and establish a baseline for each postcode or health service region. A sudden rise in cefalexin alternatives, macrolides, fluoroquinolones, or other broader-spectrum products should be interpreted alongside local guidelines and the infection types for which those medicines are prescribed.

A short increase during winter may be expected, particularly when respiratory illness rises in Melbourne or Sydney. A persistent increase after seasonal activity has declined is more concerning. The pattern becomes stronger when it appears in several nearby pharmacies, affects multiple prescribers, or coincides with more treatment failures and hospital referrals.

Building A Reliable Pharmacy Surveillance Stream

A useful system begins with a clear case definition for the signal. “Second-line antibiotic” should refer to a defined list of active ingredients and indications, with regular review as Australian prescribing guidance changes. The list should distinguish oral community medicines from hospital products, paediatric formulations, topical preparations, and prophylactic use where possible.

Data quality needs careful attention. A pharmacy sale does not prove that the patient took the medicine, had a bacterial infection, or carried a resistant organism. Stock transfers, temporary shortages, wholesaler delays, changes in pharmacy ownership, and electronic prescribing patterns can all influence the numbers. For example, a supply disruption in regional Queensland could shift dispensing to a neighbouring town and create an artificial fall in one area and an apparent surge in another.

Geography also requires local knowledge. A city pharmacy near a major hospital may serve patients from several suburbs, while a single pharmacy in the Kimberley or Far North Queensland may serve a wide, mobile population. Analysts should consider patient residence, pharmacy location, hospital catchments, and seasonal population movement separately. Data should be aggregated enough to protect privacy, especially in small communities where a few prescriptions could identify a clinical practice or facility.

The strongest design links pharmacy activity with clinical and laboratory information. A rise in second-line antibiotic dispensing paired with increased fever presentations, wound infections, or positive resistant cultures provides a more credible alert than sales data alone. School absenteeism can add context for community transmission, while aged-care surveillance may identify a separate pattern among residents with recurrent urinary or respiratory infections.

Connecting Pharmacy Signals With Other Early Warnings

Syndromic surveillance is designed to detect unusual health activity before definitive laboratory confirmation. Pharmacy data fits this model because dispensing records may be available sooner than consolidated resistance reports. A monitoring dashboard could display weekly changes in selected medicines, emergency presentations for relevant syndromes, pathology requests, and antimicrobial susceptibility results.

The interpretation should remain clinically grounded. A rise in second-line treatment for skin infections may point toward changes in community-associated Staphylococcus aureus, while increased prescribing for urinary infections may reflect local resistance in Escherichia coli. These are different hypotheses requiring different laboratory tests, clinical reviews, and responses. A general “resistance alert” would be too vague to guide action.

Experience from other surveillance applications shows why multiple channels matter. For example, invasive strep monitoring illustrates how early signals can be assembled around a serious infectious disease before all confirmatory data are available. The same principle can be applied to antibiotic use: pharmacy activity identifies a change, while clinical and laboratory sources help explain it.

A pharmacy signal may also reveal pressure on the health system rather than resistance itself. A shortage of a preferred antibiotic, a change in prescribing software, a new private telehealth service, or an outbreak in a residential-care facility can alter medicine demand. Public-health teams should therefore issue alerts for investigation, not public claims about resistant bacteria, until the supporting evidence is reviewed.

Practical Measures For Australian Health Services

Australia’s antimicrobial stewardship framework gives health services a foundation for using these signals responsibly. Community pharmacies, general practices, hospitals, pathology providers, state and territory health departments, and Primary Health Networks can contribute different pieces of the picture. Agreements should define what is shared, how quickly it is reported, and who is responsible for checking an alert.

The system should distinguish genuine clinical escalation from changes in access. During a busy winter in Brisbane, for instance, an increase in respiratory consultations may lead to more antibiotic prescriptions even when bacterial disease has not risen. In remote communities, delayed appointments or limited pathology access may encourage broader empirical treatment. These realities should be built into the baseline rather than treated as unexplained noise.

Analysts can monitor several complementary indicators:

• Second-line dispensing as a share of all systemic antibiotic dispensing
• Repeat prescriptions or treatment changes within a short interval
• Geographic clusters across pharmacies or postcodes
• Prescribing changes following a medicine shortage or guideline update

Additional safeguards can improve interpretation:

• Compare pharmacy trends with pathology susceptibility results
• Stratify findings by age, setting, indication, and season
• Review hospital and aged-care data for matching syndromes
• Share alerts through established stewardship and public-health channels

Communication is important for maintaining trust. Pharmacists and prescribers should understand that surveillance is intended to identify population-level changes, not rank individual practices. Feedback can include local benchmarks, prescribing guidance, and requests for targeted cultures. Clear governance is particularly important when data crosses state borders or combines PBS, private, hospital, and laboratory records.

Turning An Early Signal Into A Proportionate Response

Once a signal passes a predefined threshold, the next step is validation. Analysts can check whether the increase is present across independent pharmacies, whether dispensing is concentrated among a single prescriber, and whether products were supplied for a plausible infection. They can then examine culture results, emergency department records, hospital admissions, and treatment outcomes in the same period.

The response should match the strength of the evidence. A weak or isolated signal may require enhanced monitoring and a conversation with local clinicians. A sustained pattern supported by resistant isolates could prompt targeted specimen collection, infection-control advice, prescribing reminders, or an investigation of a particular facility. Broad public messaging is rarely justified by pharmacy data alone.

Other syndromic systems provide useful examples of how medicine-related data can support early detection. The analysis of opioid overdose clusters demonstrates the value of looking for changes in supply or health activity alongside clinical events. In antimicrobial resistance surveillance, a similar approach could compare dispensing anomalies with emergency presentations, ambulance callouts, and laboratory findings.

The method can also be adapted beyond antibiotics. Pharmacy purchases of epinephrine devices, for example, may contribute to monitoring allergic reactions when interpreted with emergency and clinical data, as described in epinephrine sales surveillance. These examples reinforce a central principle: pharmacy activity is most useful as an early indicator within a wider surveillance network.

A mature program should evaluate its alerts over time. Teams can measure how often a pharmacy signal was confirmed, how quickly laboratory testing followed, whether prescribing changed, and whether the response reduced unnecessary broad-spectrum use. Regular review can identify blind spots, such as under-reporting from small independent pharmacies, limited visibility of private prescriptions, or weaker coverage in remote areas.

Public-health agencies and health services can begin by selecting a small group of high-value medicines, defining local baselines, and establishing a routine review with pharmacists, prescribers, microbiologists, and epidemiologists. Linking these data with syndromic, laboratory, hospital, and aged-care information creates a faster route from an unusual dispensing pattern to a targeted, evidence-based response. Build the monitoring pathway carefully, validate every alert, and use the findings to protect antibiotic effectiveness across Australian communities.